Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia in Pediatric Crohn's Disease
NCT00899678Phase 2Terminated
- Sponsor
- UCB
- Start
- Apr 2009
- Primary completion
- Jul 2012
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of certolizumab pegol in Crohn's disease (2 arms), sponsored by UCB. Primary endpoint: Percentage of Subjects in Clinical Remission at 62 weeks. Started Apr 2009; status: terminated.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00899678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00899678.